Vaccine-induced mucosal immunity and broad protective capacity against various severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants remain inadequate …

The COVID-19 outbreak has become a global pandemic responsible for over 2,000,000
confirmed cases and over 126,000 deaths worldwide. In this study, we examined the …

The development of an effective vaccine against SARS-CoV-2 is urgently needed. We
generated SARS-CoV-2 RBD-Fc fusion protein and evaluated its potency to elicit …

Multiple safe and effective vaccines that elicit immune responses against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary to respond to the ongoing …

An effective COVID-19 vaccine against broad SARS-CoV-2 variants is still an unmet need. In
the study, the vesicular stomatitis virus (VSV)-based vector was used to express the SARS …

Mucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this
study, we tested an intranasal mucosal vaccine candidate for COVID-19 that consisted of a …

Abstract SARS-CoV-2 and SARS-CoV are genetically related coronavirus and share the
same cellular receptor ACE2. By replacing the VSV glycoprotein with the spikes (S) of SARS …

The circulating flu viruses merging with the ongoing COVID-19 pandemic raises a more
severe threat that promotes the infectivity of SARS-CoV-2 associated with higher mortality …

Aims Vaccination has played an important role in protecting against death and the severity
of COVID-19. The recombinant protein vaccine platform has a long track record of safety and …

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
presents an urgent need for an effective vaccine. Molecular characterization of SARS-CoV-2 …